The significant downregulation of survivin protein following TBG-siCK2 treatment, but not following TBG-siCDK11 treatment, suggests that downregulation of CK2 in the TBG-siCDK11-treated tumors possibly occurred too late in the acute response study to have markedly affected survivin expression at the time of tumor collection. The gene discussed is SERPINA7; the disease is neoplasm.